Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
27.32
-0.19 (-0.69%)
At close: Oct 17, 2025, 4:00 PM EDT
28.00
+0.68 (2.49%)
After-hours: Oct 17, 2025, 6:15 PM EDT
Travere Therapeutics Revenue
Travere Therapeutics had revenue of $114.45M in the quarter ending June 30, 2025, with 111.49% growth. This brings the company's revenue in the last twelve months to $333.87M, up 87.94% year-over-year. In the year 2024, Travere Therapeutics had annual revenue of $233.18M with 60.55% growth.
Revenue (ttm)
$333.87M
Revenue Growth
+87.94%
P/S Ratio
6.92
Revenue / Employee
$867,182
Employees
385
Market Cap
2.44B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
TVTX News
- 2 days ago - Travere Therapeutics to Present Abstracts at American Society of Nephrology (ASN) Kidney Week 2025 - Business Wire
- 9 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 23 days ago - CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy - Business Wire
- 4 weeks ago - 3 Potential Biotech Acquisition Targets - Seeking Alpha
- 5 weeks ago - Travere Therapeutics: Buy Rating On Back Of Filspari Expansion Towards FSGS - Seeking Alpha
- 5 weeks ago - Travere: No AdCom, No Problem - Targeting Big Revenues With FSGS Approval - Seeking Alpha
- 5 weeks ago - Travere Therapeutics Provides Update on FDA Advisory Committee Meeting for FILSPARI® (sparsentan) in FSGS - Business Wire
- 6 weeks ago - Travere Therapeutics, Inc. (TVTX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha